Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO)
(2018) 43rd ESMO Congress (ESMO 2018) — Location: (Germany) Munich (19.October.2018)
Files
2018_Ferrara_Ann_Oncol_1416P.pdf
Open Access - Adobe PDF
- 56.28 KB
Details
- Authors
- Abstract
- BACKGROUND: iSenescence is a progressive remodeling of immune functions with a multifactorial etiology (i.e. aging, chronic inflammation, cancer). Although the absence of CD28 and the expression of CD57 and Killer-cell lectin-like receptor G1 (KLRG1) on peripheral T-lymphocytes are potential hallmarks of iSenescence, the characterization of such phenotype in IO-treated aNSCLC patients and the correlation with clinical characteristics and benefit from immunotherapy are currently unknown. [...]
- Affiliations
Citations
Ferrara, R., Naigeon, M., Auclin, E., Duchemann, B., Cassard, L., Medhi, J., Boselli, L., Grivel, J., Desnoyer, A., Mezquita, L., Aboubakar Nana, F., Hendriks, L., Planchard, D., Caramella, C., Remon, J., Ngocamus, M., Nicotra, C., Besse, B., & Chaput, N. (2018). Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO). Annals of Oncology, 29(Suppl 8), viii511. https://doi.org/10.1093/annonc/mdy292.038 (Original work published 2018)